ZOTAROLIMUS

ZOTAROLIMUS Basic information
Product Name:ZOTAROLIMUS
Synonyms:ZOTAROLIMUS;(42S)-42-Deoxy-42-(1H-tetrazol-1-yl)rapamycin;A 179578;ABT 578;ABT-578;A-179578;ABT578;A179578;ABT 578;A 179578;CS-1162;Rapamycin, 42-deoxy-42-(1H-tetrazol-1-yl)-, (42S)-;Unii-H4gxr80ize
CAS:221877-54-9
MF:C52H79N5O12
MW:966.21
EINECS:
Product Categories:Inhibitors;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;Heterocycles
Mol File:221877-54-9.mol
ZOTAROLIMUS Structure
ZOTAROLIMUS Chemical Properties
Melting point 100-105°C
Boiling point 1016.2±75.0 °C(Predicted)
density 1.25
storage temp. Hygroscopic, -20°C Freezer, Under Inert Atmosphere
solubility DMSO, Methanol (Slightly)
form Solid
pka10.40±0.70(Predicted)
color White to Pale Yellow
Safety Information
HS Code 29349990
MSDS Information
ZOTAROLIMUS Usage And Synthesis
DescriptionZotarolimus is a macrocyclic lactone immunosuppressant and a derivative of rapamycin . It binds to FKBP prolyl isomerase 1A (FKBP12; IC50 = 2.57 nM) and inhibits proliferation of human peripheral blood mononuclear cells (PBMCs), rat splenocytes, and human coronary artery smooth muscle cells (IC50s = 7, 1,337, and 0.8 nM, respectively). Zotarolimus has immunosuppressive activity in a one-way mixed lymphocyte reaction using human or rat lymphocytes (IC50s = 1.2 and 1,465 nM, respectively). It also reduces symptom severity in a rat model of experimental autoimmune encephalomyelitis (EAE; ED50 = 1.17 mg/kg per day) and delays cardiac allograft rejection in rats (ED50 = 3.71 mg/kg per day). Zotarolimus inhibits neointimal formation and reduces stenosis in pig coronary arteries when applied at 10 μg/mm to stainless steel balloon expandable stents with phosphorylcholine in a model of restenosis. Formulations containing zotarolimus have been used in drug-eluting stents in the prevention of restenosis following stent placement.
Chemical PropertiesPale Yellow Solid
UsesZotarolimus is a semi-synthetic macrocyclic lactone prepared from rapamycin by preparation of the 42-triflate ester, followed by displacement with tetrazole and purification of the two isomeric products. This structural change affords a less bioavailable product, a preferred profile for some applications. Like all tacrolimus analogues, zotarolimus binds to a receptor protein (FKBP12). The complex then binds to preventing it from interacting with target proteins. Zotarolimus is extensively cited in the literature with over 200 citations.
UsesA tetrazole-containing Rapamycin analog as immunomodulator and useful in the treatment of restenosis and immune and autoimmune diseases.
DefinitionChEBI: Zotarolimus is a macrolide and a lactam.
ZOTAROLIMUS Preparation Products And Raw materials
Zonisamide ZPCK Epothilone B Z-ORN(BOC)-OH (2R)-1-{4-[(1aR,6r,10bS)-1,1-Difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cyclohepten-6-yl]piperazin-1-yl}-3-(quinolin-5-yloxy)propan-2-ol Z-N-Methyl-D-valine Trametinib Z-NVA-OH Dasatinib Saracatinib ZM 39923 HYDROCHLORIDE ZM 336372 Tepotinib ZOSUQUIDAR TRIHYSROCHLORIDE Z-NLE-OH Rapamycin ZOTAROLIMUS Ethyl1-butyl-2-piperidinecarbxylate

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.